Clinical Trial Update: Real-World Evidence of Effectiveness and Safety of Tirabrutinib in Patients with Relapsed or Refractory Primary Central Nervous System Lymphoma in Taiwan: a Nationwide Study

View source ↗

Summary

A nationwide real-world study in Taiwan assesses the effectiveness and safety of Tirabrutinib for relapsed or refractory Primary Central Nervous System Lymphoma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Lymphoma

Drugs mentioned

• Tirabrutinib (tirabrutinib)

Snippet

Sponsor: Ono Pharmaceutical Co., Ltd. | Conditions: Primary Central Nervous System Lymphoma (PCNSL) | Status: NOT_YET_RECRUITING